WO2019037133A1 - 靶向沉默APP的shRNA - Google Patents

靶向沉默APP的shRNA Download PDF

Info

Publication number
WO2019037133A1
WO2019037133A1 PCT/CN2017/099177 CN2017099177W WO2019037133A1 WO 2019037133 A1 WO2019037133 A1 WO 2019037133A1 CN 2017099177 W CN2017099177 W CN 2017099177W WO 2019037133 A1 WO2019037133 A1 WO 2019037133A1
Authority
WO
WIPO (PCT)
Prior art keywords
app
vector
shrna
silent
psuper
Prior art date
Application number
PCT/CN2017/099177
Other languages
English (en)
French (fr)
Inventor
毛吉炎
Original Assignee
深圳市博奥康生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳市博奥康生物科技有限公司 filed Critical 深圳市博奥康生物科技有限公司
Priority to PCT/CN2017/099177 priority Critical patent/WO2019037133A1/zh
Publication of WO2019037133A1 publication Critical patent/WO2019037133A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing

Definitions

  • the present invention belongs to the field of DNA recombination technology in bioengineering, and specifically relates to shRNA which specifically silences the target protein A PP .
  • AD Alzheimer's disease
  • ⁇ -amyloid precursor protein ( ⁇ ) is a single transmembrane protein having a membrane receptor-like protein structure widely present in various tissue cells of the whole body.
  • ⁇ -amyloi d ( ⁇ ) is a fragment containing 39 to 43 amino acids which is cleaved by ⁇ and ⁇ secretase in a pathological condition.
  • the relative molecular mass is about 42000, deposited in the extracellular space. Forming age spots.
  • AD has become the fourth largest disease causing human death, seriously affecting the physical and mental health and quality of life of the elderly.
  • Alzheimer's disease may cause many family social problems in susceptible populations.
  • the role of the disease in the pathogenesis of Alzheimer's disease is of great significance for the early prevention and treatment of Alzheimer's disease.
  • the existing research puts most of the energy on ⁇ , and the research on ⁇ itself is seriously insufficient. Therefore, the lack of lentiviral vectors that specifically inhibit the expression of ⁇ gene in the prior art makes the research not well developed. .
  • the object of the present invention is to synthesize a specific base sequence capable of targeting silencing, which provides an effective means for further research on the action of purines.
  • the main construct required in the present invention is a silent vector for hydrazine.
  • the construction of the core silencing vector is divided into two major steps. The first step is to design a 19 bp shRNA core fragment based on the human ⁇ sequence. With the appropriate restriction site, the fragment of interest is ligated to the pSUPER vector to form the core silencing vector
  • a 19 bp shRNA core fragment capable of targeting human APP is designed and synthesized, and the sequence thereof is
  • the sequence of the APP is specifically identified based on the human APP gene sequence using the corresponding software design.
  • the second step the artificial synthesis of double-stranded shRNA fragments
  • the linearized vector is recovered by using a recovery kit, and the recovered fragment is ligated with the shRNA fragment obtained by annealing, transformed, and the positive clone is identified, and the successfully constructed silencing vector is obtained by sequencing.
  • the plasmid was extracted, and the total RNA was extracted after transfecting the cells. After reverse transcription into cDNA, the silencing efficiency was detected by quantitative PCR.
  • the 19 bp shRNA core fragment synthesized in the present invention is designed to specifically silence APP.
  • the experimental results show that the successful construction of the vector can specifically silence the APP and reduce the expression of APP in the cell. Therefore, the application of the APP silencing vector can more closely study the function of APP and provide a theoretical basis for explaining related mechanisms.
  • FIG. 1 is a schematic diagram showing the results of quantitative PCR detection of APP gene expression by RGC5 cells after transfection of pSUPER-APP vector.
  • RGC5 cells were purchased from the Cell Resource Center of the Shanghai Institute of Biological Sciences, and the RNeasy Mini Kit was purchased from Qiagen.
  • the complete medium described below is a cell culture medium supplemented with 10% fetal bovine serum.
  • a 59 bp sequence was designed in the form of Bgl II-GN18-TT-loop-81NC-Hind III, 81NC is the reverse complement of NG18, the Bgl II cleavage site at the 5' end and the Hind III cleavage site at the 3' end. Point, the obtained sequences are respectively SEQ ID NO:
  • the synthesized shRNA oligonucleotides are mixed in equal amounts in a single strand and annealed to form a double-stranded shRNA. Take 2 g
  • the pSUPER vector, Bgl II and Hind III were digested, electrophoresed, and the linear pSUPER large fragment was recovered. Dilute the linearized pSUPER concentration to 100
  • Ng/ ⁇ , and the double-stranded shRNA obtained by annealing were ligated overnight at 4 °C with T4 DNA ligase (NEB).
  • the ligation product was transformed into ToplO competent cells and plated on LB plates with Kan resistance. Monoclonal shakes were picked on the transformation plates and cultured overnight before being sent to Shanghai Biotech for sequencing. The correct bacteria were sequenced for the extraction of endotoxin-free plasmids, and the pSUPER-APP vector was obtained.
  • Example 3 The pSUPER-APP vector transduced RGC5 cells.
  • RGC5 cells were cultured, and cells grown in good condition were inoculated into a six-well plate at 10 6 cells per well, and the cell density was about 60% after 18 h.
  • the extracted pSUPER-APP vector was transferred to 3 g using Lipofectamin 2000. Guide RGC5 cells. After 6 h, the medium was changed to fresh complete medium and cultured for 48 h.
  • RGC5 cells and RGC5 cells transduced with pSUPER-APP vector were plated separately into 6-well plates.
  • Cell density reached 80 ⁇ 3 ⁇ 4-90 ⁇ 3 ⁇ 4 ⁇
  • total RNA was extracted from each group using RNeasy Mini Kit, using PrimeScrip RT reagent Kit reverse transcribes mRNA into cDNA, reverse transcription conditions: 37 ° C, 15 min; 85 ° C, 5 s; 4 ° C, ⁇ .
  • the cDNA was diluted with 90 ⁇ l of RNase-Free dH20 and stored at -20 °C.
  • GAPDH was used as an internal reference, and the relative expression of APP was detected by real-time fluorescent quantitative PCR (QPCR).
  • QPCR real-time fluorescent quantitative PCR
  • the 19 bp shRNA core fragment synthesized in the present invention is designed to specifically silence APP.
  • the experimental results show that the successful construction of the vector can specifically silence the APP and reduce the expression of APP in the cell. Therefore, the application of the APP silencing vector can more closely study the function of APP and provide a theoretical basis for explaining related mechanisms.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

一种靶向沉默人APP基因的shRNA，其核心序列的编码核酸序列为5'-GGGAAGTGGGATTCAGATC-3'。

Description

靶向沉默 APP的 shRNA
技术领域
[0001] 本发明属于生物工程中的 DNA重组技术领域， 具体涉及特异性沉默靶标蛋白 A PP的 shRNA。
背景技术
[0002] 阿尔茨海默病 （Alzheimer's disease , AD) ， 是引起老年性痴呆的最常见原因
。 此疾病常见于老年人， 是一种进行性认知障碍和记忆能力损害为主的中枢系 统退行性变性疾病， 临床表现为认知和记忆功能不断恶化， 日常生活能力进行 性减退， 并有各种精神症状和行为障碍。 多起病于老年期， 潜隐起病， 病程缓 慢且不可逆， 临床上以智能损害为主。 β-淀粉样前体蛋白 （ΑΡΡ) 为广泛存在于 全身各组织细胞、 具有膜受体样蛋白结构的单跨膜蛋白。 β-淀粉样蛋白 (β-amyloi d， Αβ)为病理状况下 APP经 β和 γ分泌酶协同作用裂解成的含有 39〜43个氨基酸的 片段， 相对分子质量约为 42000， 沉积于细胞外间隙形成老年斑。
技术问题
[0003] 目前， AD已成为引起人类死亡的第四大疾病， 严重影响老年人的身心健康与 生命质量， 在易感人群中阿尔茨海默病可能产生诸多家庭社会问题， 研究 ΑΡΡ在 阿尔兹海默症发病过程中的作用对于阿尔兹海默症的早期防控、 对症治疗有着 很大的意义。 但现有的研究将大多数精力都放在了 Αβ上， 对于 ΑΡΡ本身的研究 投入严重不足， 因此现有技术中也缺乏特异抑制 ΑΡΡ基因表达的慢病毒载体使得 相关研究无法很好地幵展。
问题的解决方案
技术解决方案
[0004] 本发明的目的是合成特定的能够靶向沉默 ΑΡΡ的特异碱基序列， 为更加深入的 研究 ΑΡΡ的作用提供了有效的手段。
[0005] 本发明中所需要主要构建的是 ΑΡΡ的沉默载体。 核心沉默载体构建分为两个大 的步骤， 首先是根据人 ΑΡΡ序列设计出 19bp的 shRNA核心片段， 所合成片段两端 带有合适的酶切位点， 将目的片段连接到 pSUPER载体上， 形成核心的沉默载体
， 转化后， 挑取阳性克隆进行 PCR鉴定。 鉴定正确的载体， 进行 DNA测序， 随 后通过免疫印记实验进行沉默效率的检测。
[0006] 本发明中设计合成了一个能够靶向人 APP的 19bp的 shRNA核心片段， 其序列为
5'- GGGAAGTGGGATTCAGATC -3' (SEQ ID No: l) 。
[0007] 特异性沉默 APP的表达载体的构建包括以下步骤：
[0008] 第一步， shRNA片段序列设计
[0009] 根据人 APP基因序列应用相应的软件设计特异性识别 APP的序列。
[0010] 第二步， 双链 shRNA片段的人工合成
[0011] 将人工合成的 Sense (SEQ ID No: 2) 和 Antisense (SEQ ID No: 3) 通过变性、 退火形成双链 DNA。
[0012] 第三步， 沉默载体的构建
[0013] 将沉默载体 pSUPER双酶切后,利用回收试剂盒回收线性化载体， 将回收片段与 退火所得的 shRNA片段进行连接、 转化、 鉴定阳性克隆、 测序得到构建成功的 沉默载体。
[0014] 第四步， 沉默靶蛋白效率的检测
[0015] 提取质粒， 转染细胞后提取总 RNA， 逆转录为 cDNA后利用定量 PCR检测沉默 效率。
发明的有益效果
有益效果
[0016] 本发明中设计合成的 19bp的 shRNA核心片段， 能够特异性的沉默 APP。 实验结 果表明， 构建成功的载体， 能够特异性的沉默 APP， 降低细胞内 APP的表达。 因 此， APP沉默载体的应用能够更为精细地研究 APP的功能， 为解释相关机制提供 理论基础。
对附图的简要说明
附图说明
[0017] 图 1为转染 pSUPER-APP载体后 RGC5细胞的定量 PCR检测 APP基因表达情况结 果示意图。 实施该发明的最佳实施例
本发明的最佳实施方式
[0018] 下面结合附图与具体实施例对本发明做进一步的说明。
[0019] RGC5细胞购自上海生命科学院细胞资源中心， RNeasy Mini Kit购自 Qiagen公 司。 下文所述完全培养基为加入了 10%胎牛血清的细胞培养基。
[0020] 实施例一 shRNA寡核苷酸序列的设计
[0021] 在 GenBank査找到 APP的 mRNA全序列， 经 BLAST同源性比对证实特异性后应 用 RNAstmcture 4.4软件对靶 mRNA序列的二级结构进行评估， 最后获得靶核苷 酸序列， 如 SEQ ID NO: 1所示。
[0022] 以 Bgl II-GN18-TT-loop-81NC-Hind III形式设计 59bp序列， 81NC为 NG18的反向 互补， 5'端为 Bgl II酶切位点， 3'端为 Hind III酶切位点， 所获序列分别如 SEQ ID
NO: 2和 SEQ ID NO: 3所示。
[0023] 实施例二 shRNA慢病毒表达载体的构建
[0024] 将合成的 shRNA寡核苷酸单链等量混合， 退火形成双链的 shRNA。 取 2 g
pSUPER载体， Bgl II和 Hind III双酶切， 电泳， 回收线性 pSUPER大片段。 将线 性化 pSUPER浓度稀释至 100
ng/μί, 与退火所得双链 shRNA用 T4DNA连接酶 （NEB) 4°C连接过夜。 将连接 产物转化 ToplO感受态细胞， 涂布在具有 Kan抗性的 LB平板上。 在转化平板上挑 取单克隆摇菌， 培养过夜后送至上海生工测序。 测序正确的菌用于无内毒素质 粒的提取， 获得 pSUPER- APP载体。
[0025] 实施例三 pSUPER-APP载体转导 RGC5细胞。
[0026] 培养 RGC5细胞， 取生长状态良好的细胞接种到六孔板中， 每孔 10 6个细胞， 18 h后细胞密度约为 60%， 利用 Lipofectamin 2000将提取的 pSUPER- APP载体 3 g转 导 RGC5细胞。 6 h后， 将培养基换为新鲜的完全培养基继续培养 48 h。
[0027] 实施例四 APP基因表达水平检测
[0028] 分别接种 RGC5细胞和转导了 pSUPER-APP载体的 RGC5细胞至 6孔板。 细胞密 度达到 80<¾-90<¾吋， 用 RNeasy Mini Kit提取各组细胞的总 RNA， 利用 PrimeScrip RT reagent Kit将 mRNA逆转录为 cDNA， 逆转录条件： 37°C， 15min; 85°C， 5s; 4°C， ∞。 反转录结束后， 加入 90μ1的 RNase-Free dH20稀释 cDNA， -20°C保存。
[0029] 取各组细胞的 cDNA 1
为模板， 以 GAPDH为内参， 实吋荧光定量 PCR (QPCR) 检测 APP相对表达量 ， 设置反应条件： 95°C 10s， 1个循环； 95°C 5s， 60°C
30s， 共 40个循环， 利用 SYBR Primescript RT-PCR Kit检测各组细胞 APP基因相对 表达量， 结果如图 2所示。 结果显示转导了 pSUPER-APP载体的 RGC5细胞， APP 基因表达明显受到抑制， 干扰片段对目的基因的抑制效率达 81.2%±3.7%， 从而 证明本实验中采用的 pSUPER-APP载体能特异抑制 APP基因的表达， 且抑制效果 非常显著。
[0030] 以上内容是结合具体的优选实施方式对本发明所作的进一步详细说明， 不能认 定本发明的具体实施只局限于这些说明。 对于本发明所属技术领域的普通技术 人员来说， 在不脱离本发明构思的前提下， 还可以做出若干简单推演或替换， 都应当视为属于本发明的保护范围。
工业实用性
[0031] 本发明中设计合成的 19bp的 shRNA核心片段， 能够特异性的沉默 APP。 实验结 果表明， 构建成功的载体， 能够特异性的沉默 APP， 降低细胞内 APP的表达。 因 此， APP沉默载体的应用能够更为精细地研究 APP的功能， 为解释相关机制提供 理论基础。

Claims

权利要求书
[权利要求 1] 靶向沉默人 APP基因的 shRNA, 其特征是 shRNA核心序列为 5'-
GGGAAGTGGGATTCAGATC -3，。
PCT/CN2017/099177 2017-08-25 2017-08-25 靶向沉默APP的shRNA WO2019037133A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/099177 WO2019037133A1 (zh) 2017-08-25 2017-08-25 靶向沉默APP的shRNA

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/099177 WO2019037133A1 (zh) 2017-08-25 2017-08-25 靶向沉默APP的shRNA

Publications (1)

Publication Number Publication Date
WO2019037133A1 true WO2019037133A1 (zh) 2019-02-28

Family

ID=65438263

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/099177 WO2019037133A1 (zh) 2017-08-25 2017-08-25 靶向沉默APP的shRNA

Country Status (1)

Country Link
WO (1) WO2019037133A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11732260B2 (en) 2018-03-02 2023-08-22 Ionis Pharmaceuticals, Inc. Compounds and methods for the modulation of amyloid-β precursor protein

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101946001A (zh) * 2007-12-20 2011-01-12 安吉奥开米公司 多肽-核酸结合物及其应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101946001A (zh) * 2007-12-20 2011-01-12 安吉奥开米公司 多肽-核酸结合物及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
C-S HONG ET AL.: "Herpes Simplex Virus RNAi and Neprilysin Gene Transfer Vectors Reduce Accumulation of Alzheimer's Disease-related Amyloid-beta Peptide in Vivo", GENE THERAPY, vol. 13, no. 14, 16 March 2006 (2006-03-16), pages 1068 - 1079, XP002550732, ISSN: 1476-5462, DOI: doi:10.1038/sj.gt.3302719 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11732260B2 (en) 2018-03-02 2023-08-22 Ionis Pharmaceuticals, Inc. Compounds and methods for the modulation of amyloid-β precursor protein

Similar Documents

Publication Publication Date Title
CN107502608B (zh) 用于敲除人ALDH2基因的sgRNA、ALDH2基因缺失细胞株的构建方法及应用
CN103429743B (zh) 构建特异性启动子的方法
CN105985978B (zh) 一种新型rna环化表达载体的构建及其应用
CN109022436B (zh) 特异抑制3β-HSD基因表达的shRNA重组载体构建与应用
WO2019037133A1 (zh) 靶向沉默APP的shRNA
CN101838648A (zh) 抑制小鼠TRAF6基因表达的shRNA及其应用
CN111676222A (zh) 抑制Mettl3基因表达的shRNA及其重组腺相关病毒与应用
WO2019037057A1 (zh) 靶向沉默 DD1 α的 shRNA
CN109136377B (zh) 成人t细胞白血病的治疗药物及诊断试剂盒
CN103710372B (zh) 一种用于功能研究的miR-505高表达载体的构建方法
WO2017214940A1 (zh) 特异促进Cplx2基因高表达的慢病毒表达载体及其应用
CN110964727A (zh) 特异抑制c-myc基因表达的shRNA慢病毒表达载体构建方法与应用
CN111206050A (zh) 过表达hACE2基因的NK细胞制剂的制备方法
JP2022515211A (ja) 合成マイクロｒｎａミミック
WO2019037052A1 (zh) 靶向沉默wucam的shrna
WO2019037130A1 (zh) 人 AMPAR 基因的 shRNA 及其应用
WO2019036872A1 (zh) 敲低PTA1基因表达的shRNA
CN109971757A (zh) 一种双sgRNA位点敲除FOXR1基因的CRISPR/Cas9系统与应用
WO2019000145A1 (zh) 一种ampar高表达的重组cho细胞的构建方法
CN109097359B (zh) 抑制StAR基因表达的shRNA重组载体构建与应用
WO2019000148A1 (zh) 一种人ABCB6基因的siRNA及其应用
WO2017214937A1 (zh) 一种促进 app 基因表达的慢病毒表达载体及其应用
WO2018170764A1 (zh) 一种用于 RNAi 的载体及其应用
WO2019033246A1 (zh) 共敲减三种 miRNA 表达的 Tud RNA 及其应用
WO2019037053A1 (zh) 人 AITR 基因的 shRNA 及其应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17922681

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17922681

Country of ref document: EP

Kind code of ref document: A1